Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1Stomach Neoplasms 1Smoking Cessation 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Hematuria 1Carcinoma, Transitional Cell 1

Interventions

fludarabine 5Cyclophosphamide 5Cyclosporine 4fludarabine phosphate 3Whole-Body Irradiation 3Imatinib Mesylate 3Therapeutics 2Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Methotrexate 2Hematologic Tests 2Busulfan 2Antilymphocyte Serum 2thymoglobulin 1nilotinib 1bosutinib 1Urinalysis 1Transplantation, Homologous 1Tetanus Toxoid 1Standard of Care 1Resistance Training 1Registries 1Radiotherapy 1Pharmaceutical Services 1Ondansetron 1Nurse Clinicians 1Modafinil 1Melphalan 1Health Promotion 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Urinalysis × Clear all
NCT00580281 2013-10-24

Effect of Imatinib on Bone Metabolism in Patients With Chronic Myelogenous Leukemia or Gastrointestinal Stromal Tumors

Memorial Sloan Kettering Cancer Center

Phase NA Completed
33 enrolled
GastrointestinalMyeloidOther hematologic neoplasm

Leukemia, Stomach Neoplasms, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡